Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
29 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Teva Investigational Site 313
Montreal, Canada
- Teva Investigational Site 309
Toronto, Canada
- Teva Investigational Site 329
Bordeaux, France
- Teva Investigational Site 321
Le Chesnay, France
- Teva Investigational Site 322
Lille, France
- Teva Investigational Site 320
Lyon, France
- Teva Investigational Site 324
Nice, France
- Teva Investigational Site 328
Paris, France
- Teva Investigational Site 323
Poitiers, France
- Teva Investigational Site 327
Strasbourg, France
- Teva Investigational Site 325
Toulouse, France
- Teva Investigational Site 331
Berlin, Germany
- Teva Investigational Site 330
Mannheim, Germany
- Teva Investigational Site 350
Budapest, Hungary
- Teva Investigational Site 371
Hyderabad, India
- Teva Investigational Site 370
Mumbai, India
- Teva Investigational Site 390
Bologna, Italy
- Teva Investigational Site 360
Gdansk, Poland
- Teva Investigational Site 361
Warsaw, Poland
- Teva Investigational Site 380
Singapore, Singapore
- Teva Investigational Site 340
London, United Kingdom
- Teva Investigational Site 303
Los Angeles, California, United States
- Teva Investigational Site 308
Beech Grove, Indiana, United States
- Teva Investigational Site 311
Baltimore, Maryland, United States
- Teva Investigational Site 305
Buffalo, New York, United States
- Teva Investigational Site 302
The Bronx, New York, United States
- Teva Investigational Site 310
Philadelphia, Pennsylvania, United States
- Teva Investigational Site 301
Houston, Texas, United States
- Teva Investigational Site 314
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Mar 2007
- Primary completion
- 4 Aug 2009
- Completion
- 27 Jun 2013
- Last update posted
- 28 Dec 2021
- Registered enrollment
- 100
- Registry id
- NCT00462943
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.